medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2011, Number 4

<< Back Next >>

An Med Asoc Med Hosp ABC 2011; 56 (4)

Gastrointestinal stromal tumors (GIST). Seven cases treated at the Centro Médico Nacional 20 de Noviembre, ISSSTE

González AJM, Ortega MBA, Rosas ZL, D´Obaldía CG, De La Fuente GM, Reyes PAS, Navarro SS

Language: Spanish
References: 64
Page: 184-195
PDF size: 133.24 Kb.


ABSTRACT

Introduction: The treatment of gastrointestinal stromal tumors (GIST) localized remains surgery. Traditionally played a palliative surgery in patients with locally advanced or metastatic GIST. The integration of targeted molecular agents surgery for GIST, leads us to reassess the role of surgery in this disease. Material and methods: We present 7 patients diagnosed with gastrointestinal stromal tumor. Five patients underwent surgery and two postoperative were sent to us to assess adjuvant treatment, at the Centro Médico Nacional 20 de Noviembre, ISSSTE. They were six men and one woman, average age of 57.1 years. While primary sites located in the retroperitoneum (2), stomach (2), ileum (2) and rectum (1). Six high-grade tumors and one intermediate grade. Four patients received the benefits of the tyrosine kinase inhibitor, of these, two with stable disease and two as adjuvant therapy for one year. Discussion: Surgical resection after therapy with imatinib or sunitinib may be curative in some patients with advanced disease, those who study with stable disease or limited progression, by treating with kinase inhibitors have a prolonged overall survival after undergoing cytoreductive procedures. Through the removal of clones of the disease who have developed resistance to drugs, surgical cytoreduction can prolong survival in patients with metastatic disease as long as remaining responsive to medication. Active and future research delineated the most effective ways to integrate surgery and targeted therapy to reduce recurrence after resection of the primary disease and prolong survival in metastatic disease.


REFERENCES

  1. Dagher R, Cohen M, Williams G et al. Approval summary: Imitanib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002; 8: 3034-3038.

  2. FDA Approves New Treatment for Gastrointestinal and Kidney Cancer, P06-11, Rockville, MD, U.S. Food and Drug Administration, 2006, www.fda.gov/bbs/topics/news/2006/NEW01302.html

  3. Demetri GD, Benjamin R, Blanke CD, et al. Optimal management of patients with gastrointestinal stromal tumors (GIST): expansion and update of NCCN Clinical Practice Guidelines. J NCC N 2004; 2 (1): 1-26.

  4. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP et al. Consensus meeting for the management of gastrointestinal stromal tumors: Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-578.

  5. Raut ChP, Posner M, Desai J, Morgan JA et al. Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors. J Clin Oncol 2006; 24 (15): 2325-2331.

  6. DeMatteo RP, Lewis JL, Leung D et al: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231 (1): 51-58.

  7. Pidhorecky I, Cheney RT, Kraybill WG, et al: Gastrointestinal stromal tumors: Current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7: 705-712.

  8. Casper ES: Gastrointestinal stromal tumors. Curr Treat Options Oncol 2000; 1: 267-273.

  9. Conlon KC, Casper ES, Brennan MF: Primary gastrointestinal sarcomas: Analysis of prognostic variables. Ann Surg Oncol 1995; 2: 26-31.

  10. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensivity to imatinib. J Clin Oncol 2005; 23 (23): 5337-5364.

  11. DeMatteo RP, Shah A, Fong Y et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234: 540-548.

  12. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152 (5): 1259-1269.

  13. Fletcher /Fletcher CD, Berman JJ, Corless C, Gornstein F, Lasota J, Longley J et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33 (5): 459-465.

  14. Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg 1996; 33: 817-872.

  15. Crosby JA, Catton CN, Davis A et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8: 50-59.

  16. Nishida T, Hiroita SI. Biological and clinical review of stromal tumors in the gastrointestinal Tract. Histol Histopathol 2000; 15: 1293-1301.

  17. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer 1995; 75 (1): 154-170.

  18. Tran T, Davila JA et al. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am G Gastroenterol 2005; 100 (1): 162-168.

  19. Pierie J-PEN, Choudry U, Muzikansky A et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136: 383-389.

  20. Singer S, Rubin BP, Lux ML et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20: 3898-3905.

  21. Fujimoto Y, Nakanishi Y, Yoshimura K et al. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003; 6: 39-48.

  22. Langer C, Gunawan B, Schuler P et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003; 90: 332-339.

  23. Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 2005; 103(4): 821-829.

  24. Nishida T, Hirota S, Taniguchi M et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998; 19: 323-324.

  25. Chompret A, Kannengiesser C, Barrois M et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004; 126: 318-321.

  26. Kindblom LG. Gastrointestinal Stromal Tumors; Diagnosis, Epidemiology, Prognosis. ASCO Annual Meeting, Chicago 2003.

  27. Miettinen M, Sobón LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, inmunohistochemical, and molecular genetic study of 1765 cases with long-term folow-up. Am J Surg Pathol 2005; 29 (1): 52-68.

  28. D´Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005; 12 (1): 44-56

  29. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumors. Br J Surg 2003; 90 (10): 1178-1186.

  30. Alvarado-Cabrero I, Barret ZR, Benítez AH, Flores GJP, Medrano GR, Torres VS, Medina FH. Lineamientos actualizados en abordaje de tumores del estroma gastrointestinal (GIST) en México. Gamo 2008; 7 (1): 1-18.

  31. Escudero de los Ríos PM, Luévano FE, Quiroz CO, Torres VS, Ocho CFJ, Oñate OLF et al. Lineamientos actualizados en el tratamiento de los tumores del estroma gastrointestinal (GIST) en México. Gamo 2011; 9 (6): 3-16.

  32. Dematteo RPRP, Maki RGRG, Antonescu CC et al. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg 2003; 40: 144-193.

  33. Bauer S, Corless CL, Heinrich MC et al. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003; 51: 261-265.

  34. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002; 38: S37-S38.

  35. Pidhorecky J, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7: 705-712.

  36. Levy A, Remotti H, Thompson WM, Sobin LH, Miettinen M. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics 2003; 23: 283-304.

  37. Emory TS, Sobin LH, Lukes L et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-87.

  38. Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: The Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117 (2): 289-293.

  39. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-519.

  40. Kindblom LG, Meis Kindblom J, Bumming P et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal tumors (GIST): a population-based study of 600 cases. Ann Oncol 2003; 13: 157.

  41. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM). Soft Tissue Sarcoma, Version 2. 2011. Gastrointestinal Stromal Tumors (GIST)GIST 1-7, GIST A-E. Disponible en: http://www.nccn.org/clinical_trials/physician.html

  42. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.

  43. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710.

  44. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.

  45. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22 (18): 3813-3825.

  46. West RB, Corless CL, Chen X. The novel marker DOG-1 is expressed ubiquitously in GIST irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004; 165: 107-113.

  47. Miettinen M, El-Rifai WE, Leslie HS et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33: 478-483.

  48. Subramanian S, West RB, Corless CL et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 2004; 23: 7780-7790.

  49. Kim TW, Lee H, Kang Y-K et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004; 10: 3076-3081.

  50. Miettinem M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30: 1213-1220.

  51. Gold JS, De Matteo RP. Tratamiento quirúrgico y molecular combinado. Ann Surg 2006; 244: 176-184.

  52. Ghanem N, Altehoefer C, Furtwangler A et al. Computed tomography in gastrointestinal stromal tumors. Eur Radiol 2003; 13 (7): 1669-1678.

  53. Lau S, Tam KF, Kam CK et al. Imaging of gastrointestinal stromal tumour (GIST). Clin Radiol 2004; 59 (6): 487-498.

  54. Heinrich MC, Corless CL, Gastric GI. Stromal tumors (GISTs): The role of surgery in the era of targeted therapy. J Surg Oncol 2005; 90 (3): 195-207.

  55. De Matteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33 (5): 466-477.

  56. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.

  57. Demetri GD, van Oosterom AT, Blackstein M et al. Phase III, multicenter, randomized, doubleblind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. J Clin Oncol 2005; 23: 308.

  58. DeMatteo RP, Antonescu CR, Chadaram V et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. J Clin Oncol 2005; 23: 818. Abstract.

  59. Samiian L, Weaver M, Velanovich V. Evaluation of gastrointestinal stromal tumors for recurrence rates and patterns of long-term follow up. Am Surg 2004; 70 (3): 187-192.

  60. Choi H, Charnsangavej C, Faria S et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenology 2004; 183: 1619-1628.

  61. Eisenberg B, Judson I. Surgery and Imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11 (5): 465-475

  62. Zalcberg J, Verweij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal tumors crossing over to a daily imatinib dose of 800 mg after progresion on 400 mg. Eur J Cancer 2005; 41 (12): 1751-1757.

  63. Demetri GD, Desai J, Fletcher JA et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib resistance caused by diverse genomic mechanisms in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2004; 22 (14): 3001.

  64. Desai J, Maki R, Heinrich MC et al. Activity and tolerability of the multi-target tyrosine Kinase inhbitor SU011248 in patients with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. 2004 Gastrointestinal Cancer Symposium, San Francisco, 2004.




2020     |     www.medigraphic.com